

State of Arkansas
95th General Assembly
Regular Session, 2025

A Bill

HOUSE BILL 1619

By: Representative Gramlich

By: Senator Irvin

For An Act To Be Entitled

AN ACT TO SET ADMINISTRATION FEES UNDER THE ARKANSAS
MEDICAID PROGRAM FOR IMMUNIZATIONS AND MONOCLONAL
ANTIBODIES FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE;
TO PROVIDE CIVIL IMMUNITY FOR ADMINISTRATION OF
IMMUNIZATIONS AND MONOCLONAL ANTIBODIES FOR
RESPIRATORY SYNCYTICAL VIRUS DISEASE; AND FOR OTHER
PURPOSES.

Subtitle

TO SET ADMINISTRATION FEES UNDER THE
ARKANSAS MEDICAID PROGRAM FOR
IMMUNIZATIONS AND MONOCLONAL ANTIBODIES
FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE;
AND TO PROVIDE CIVIL IMMUNITY.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:

SECTION 1. Arkansas Code Title 20, Chapter 77, Subchapter 4, is amended to add an additional section to read as follows:

20-77-408. Administrative fees for immunizations and monoclonal antibodies for respiratory syncytial virus disease – Definition.

(a) As used in this section, "respiratory syncytial virus disease" means a respiratory infection of the nose, throat, and lungs caused by the respiratory syncytial virus.

(b) The Arkansas Medicaid Program shall reimburse an administration fee that is equal to one hundred percent (100%) of the maximum administration fee of the Vaccines for Children Program for this state for administration of



an immunization or monoclonal antibody used for long-lasting protection from respiratory syncytial virus disease in infants and toddlers, regardless of the category in which the beneficiary receiving the immunization or monoclonal antibody is enrolled, including without limitation the Medicaid Provider-Led Organized Care Act, § 20-77-2701 et seq.

(c) This section does not require a hospital licensed under § 20-9-213 to provide any new or additional service related to administering the immunization or monoclonal antibody used for long-lasting protection from respiratory syncytial virus disease in infants and toddlers.

(d) The Department of Human Services shall apply for any federal waiver, Medicaid state plan amendment, or other authority necessary to implement this section.

SECTION 2. Arkansas Code Title 16, Chapter 114, Subchapter 2, is amended to add an additional section to read as follows:

16-114-214. Immunity related to administration of immunization or monoclonal antibody used for long-lasting protection from respiratory syncytial virus disease – Definition.

(a) As used in this section, "respiratory syncytial virus disease" means a respiratory infection of the nose, throat, and lungs caused by the respiratory syncytial virus.

(b)(1) A person or entity that prescribes, dispenses, administers, or is otherwise involved in the administration of an immunization or monoclonal antibody used for long-lasting protection from respiratory syncytial virus disease in infants and toddlers to an eligible patient is immune from civil liability.

(2) A person or entity is not immune from civil liability for actions taken during the administration of an immunization or monoclonal antibody that:

(A) Are grossly negligent, reckless, or willful; or

(B) Are not taken in good faith and with reasonable care.

APPROVED: 4/16/25